Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
2/7/25 Novo Nordisk (NVO) Mim8 for Hemophilia A Subscribers Only Subscribers Only Subscribers Only
2/5/25 Revalesio RNS60 for Ischemic Stroke Subscribers Only Subscribers Only Subscribers Only
2/4/25 Cumberland Pharmaceuticals (CPIX) Ifetroban, Cumberland Pharmaceuticals for Duchenne Muscular Dystrophy (DMD) Subscribers Only Subscribers Only Subscribers Only
2/4/25 LEO Anzupgo for Atopic Dermatitis (Eczema) Subscribers Only Subscribers Only Subscribers Only
2/3/25 GH Research (GHRS) GH001 for Major Depressive Disorder (MDD) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
02/05/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
02/06/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
02/06/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
02/06/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
02/06/2025 Subscribers Only Subscribers Only Trial Data - Updated Results